Nintedanib: from discovery to the clinic

…, C Dallinger, R Schlenker-Herceg… - Journal of medicinal …, 2015 - ACS Publications
Nintedanib (BIBF1120) is a potent, oral, small-molecule tyrosine kinase inhibitor, also known
as a triple angiokinase inhibitor, inhibiting three major signaling pathways involved in …

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases

…, S Stowasser, R Schlenker-Herceg… - European …, 2019 - Eur Respiratory Soc
A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive
phenotype characterised by decline in lung function, worsening quality of life and early …

[HTML][HTML] Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

…, S Stowasser, R Schlenker-Herceg… - … England Journal of …, 2014 - Mass Medical Soc
Background Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …

[HTML][HTML] Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey

…, P Patnaik, L Wallace, R Schlenker-Herceg… - Advances in …, 2021 - Springer
Some patients with interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis
exhibit a progressive clinical phenotype. These chronic progressive fibrosing ILDs have a …

[HTML][HTML] Nintedanib in progressive fibrosing interstitial lung diseases

…, RG Goeldner, R Schlenker-Herceg… - … England Journal of …, 2019 - Mass Medical Soc
Background Preclinical data have suggested that nintedanib, an intracellular inhibitor of
tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the …

Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement

…, R Schlenker-Herceg… - American journal of …, 2006 - atsjournals.org
Rationale: Evidence suggests that tumor necrosis factor (TNF)-α plays an important role in
the pathophysiology of sarcoidosis. Objectives: To assess the efficacy of infliximab in …

A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma

…, E Kerwin, R Schlenker-Herceg… - American journal of …, 2009 - atsjournals.org
Rationale: The treatment effect of golimumab, a human monoclonal antibody against tumor
necrosis factor (TNF)-α, in severe persistent asthma is unknown. Objectives: To assess the …

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease

…, R Watt, KH Lo, R Schlenker-Herceg… - American journal of …, 2007 - atsjournals.org
Rationale: Chronic obstructive pulmonary disease (COPD) is a progressive, smoking-related,
inflammatory lung disease in which tumor necrosis factor-α is overexpressed and has …

[HTML][HTML] Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials

…, M Selman, T Kimura, Z Bailes, R Schlenker-Herceg… - Respiratory …, 2016 - Elsevier
Background and purpose The Phase II TOMORROW trial and two Phase III INPULSIS ® trials
investigated the efficacy and safety of nintedanib versus placebo in patients with idiopathic …

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised …

…, RG Goeldner, R Schlenker-Herceg… - The lancet Respiratory …, 2020 - thelancet.com
Background The INBUILD trial investigated the efficacy and safety of nintedanib versus
placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than …